Osaic Holdings’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-16,161
| Closed | -$20.6K | – | 7621 |
|
|
2023
Q3 | $20.6K | Sell |
16,161
-20,949
| -56% | -$18.3K | ﹤0.01% | 5539 |
|
|
2023
Q2 | $12.2K | Sell |
37,110
-499
| -1% | -$179 | ﹤0.01% | 5864 |
|
|
2023
Q1 | $15.5K | Buy |
37,609
+6,250
| +20% | +$3.29K | ﹤0.01% | 5715 |
|
|
2022
Q4 | $16K | Buy |
31,359
+200
| +0.6% | +$127 | ﹤0.01% | 5726 |
|
|
2022
Q3 | $24K | Sell |
31,159
-1,300
| -4% | -$1.48K | ﹤0.01% | 5457 |
|
|
2022
Q2 | $38K | Buy |
32,459
+16,165
| +99% | +$20.6K | ﹤0.01% | 5165 |
|
|
2022
Q1 | $140K | Buy |
16,294
+3,632
| +29% | +$8.64K | ﹤0.01% | 4320 |
|
|
2021
Q4 | $36K | Buy |
12,662
+1,760
| +16% | +$6.51K | ﹤0.01% | 5398 |
|
|
2021
Q3 | $46K | Sell |
10,902
-450
| -4% | -$2.01K | ﹤0.01% | 5184 |
|
|
2021
Q2 | $59K | Sell |
11,352
-573
| -5% | -$2.75K | ﹤0.01% | 4922 |
|
|
2021
Q1 | $55K | Buy |
11,925
+590
| +5% | +$2.67K | ﹤0.01% | 4826 |
|
|
2020
Q4 | $36K | Sell |
11,335
-9,800
| -46% | -$37.2K | ﹤0.01% | 4794 |
|
|
2020
Q3 | $69K | Sell |
21,135
-11,020
| -34% | -$40.5K | ﹤0.01% | 4084 |
|
|
2020
Q2 | $108K | Buy |
32,155
+1,369
| +4% | +$6.47K | ﹤0.01% | 3631 |
|
|
2020
Q1 | $118K | Buy |
+30,786
| New | +$143K | ﹤0.01% | 3338 |
|
Osaic Holdings's ZYNE Position: Q4 2023 in Review
Osaic Holdings sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 16,161 shares — an estimated $20.6K sold.
Osaic Holdings first reported a position in ZYNE in Q1 2020 and held it in 15 quarters. The position peaked at $140K in Q1 2022. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.
- Osaic Holdings reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
- Osaic Holdings sold 16,161 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $20.6K.
- Osaic Holdings first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2020 and held it in 15 quarters.
- Osaic Holdings's Zynerba Pharmaceuticals, Inc position peaked at $140K in Q1 2022.
- 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.
Based on Osaic Holdings's 13F filing for Q4 2023, filed 12 Feb 2024.